|
|
Post by trenddiver on Oct 27, 2014 22:44:44 GMT -5
|
|
|
|
Post by kc on Oct 28, 2014 11:05:14 GMT -5
The board of directors has caused the point drop by allowing this conflict with Viehbacher to become a public debate. The document that is found on the net should have never been out there for public consumption. If they have a no confidence issue in Viehbacher then they should fire him. But now the damage has been done to their share pricing. The drop in PPS is because of this public document. That is very unprofessional on his part or the part of Management to have allowed it to get to this point.
The Chairman of the board either needs to give him the vote of confidence or fire him right away.
|
|
|
|
Post by otherottawaguy on Oct 28, 2014 11:13:50 GMT -5
Someone stated that he has been a the helm for the period where the share price has risen from 25 to 50 range. This squabble seems to have trimmed 10%.
OOG
|
|
|
|
Post by kc on Oct 28, 2014 11:44:12 GMT -5
Viehbacher alledgedly wrote this letter that was leaked to a French Newspaper asking the Board of Directors for a Vote of confidence or to remove him. If this is a real letter then you can see why the shares are tumbling. On Monday they board met together in the Boston location and did not invite Viehbacher to the meeting that was held over lunch. Perhaps there is something there perhaps not. But the share drop is not due to MannKind or Afrezza. Its due to instablilty of the company.
the letter can be seen at this link. www.slideshare.net/jm_cedro/sanofi-lettre-confidentielle-de-chris-viehbacher
or this pdf download.
Attachment Deleted |
|
|
|
Post by trenddiver on Oct 28, 2014 16:26:20 GMT -5
Maybe a good time to looking at picking up some SNY. That way have some exposure to both sides of the Afrezza partnership and the future GLP-1.
|
|
|
|
Post by jpg on Oct 28, 2014 16:35:15 GMT -5
Maybe a good time to looking at picking up some SNY. That way have some exposure to both sides of the Afrezza partnership and the future GLP-1. Maybe but if the Board want to turn back the clock on Sanofi (by firing the current CEO because he is 'overly international' as some suggest) to make Sanofi 'more French' I wouldn't be as confident in the future of Sanofi. These crony 'old boys club' French Board of Directors can really kill any innovation quickly... JPG |
|
|
|
Post by dreamboatcruise on Oct 28, 2014 16:46:37 GMT -5
Maybe a good time to looking at picking up some SNY. That way have some exposure to both sides of the Afrezza partnership and the future GLP-1. I added to my SNY today. |
|
|
|
Post by mannmade on Oct 28, 2014 17:26:51 GMT -5
The board of directors has caused the point drop by allowing this conflict with Viehbacher to become a public debate. The document that is found on the net should have never been out there for public consumption. If they have a no confidence issue in Viehbacher then they should fire him. But now the damage has been done to their share pricing. The drop in PPS is because of this public document. That is very unprofessional on his part or the part of Management to have allowed it to get to this point. The Chairman of the board either needs to give him the vote of confidence or fire him right away. I agree with Trend... Might also be a good time to buy a few shares... Oops... I am overweighted in Mannkind...  |
|
|
|
Post by jpg on Oct 28, 2014 19:08:23 GMT -5
Maybe a good time to looking at picking up some SNY. That way have some exposure to both sides of the Afrezza partnership and the future GLP-1. I added to my SNY today. Hi DBC, I would also like to eventually pick up some Sanofi because I like where they are going overall but usually really fear investing in any French company because I know well how they often act and treat shareholders. Sanofi has, over the last few years transformed itself into one of the more transparent and trustworthy public French companies but these latest event remind me of the 'good old corporate France'. From the little I understand of this public Sanofi fight it seems to be between the old guard (and proponents of "la belle époque") vs modernizers who want to build an international Sanofi. Is this in your opinion even remotely accurate? Do you understand what this public management fight for control is all about? In your opinion why does the board want to fire Viehbacher? And to replace him with which type of CEO? And finally for what purpose? Thank you for any insight you would share, JPG |
|
|
|
Post by dreamboatcruise on Oct 28, 2014 19:30:47 GMT -5
I wish I had some particular insight into what this squabble might mean. My SNY position is only a fraction of what I have in MNKD. They have a decent yield which I think limits the downside and I view Afrezza as potentially a driver for some reasonable growth that likely isn't factored in yet. The drop today seemed a bit overdone.
|
|
|
|
Post by liane on Oct 29, 2014 5:20:30 GMT -5
I moved a few of the posts this morning to "Drugmaker Sanofi Fired Its CEO In An Early Morning Meeting" so we can consolidate in one thread.
|
|
|
|
Post by seanismorris on Oct 29, 2014 20:18:31 GMT -5
Sanofi CEO's firing is a non event for Mannkind. If Peirre Chancel was fired I'd be concerned but that didn't happen. I think Sanofi's diabetes strategy remains intact. Sanofi stock is a potential buy after the sell off...
Old Quote regarding Afrezza within Sanofi
“It is not going to be in competition” with existing products, “it’s going to be a nice complement and upgrade to our portfolio,” said Pierre Chancel, senior vice president of Sanofi’s diabetes division.
|
|
|
|
Post by seanismorris on Oct 30, 2014 0:00:38 GMT -5
Wouldn't it be interesting if Mr. Viehbacher became CEO of Mannkind...
He'd have to take a massive pay cut, but he could build it into a powerhouse.
|
|
|
|
Post by seanismorris on Oct 30, 2014 12:41:40 GMT -5
I picked up 500 shares of Sanofi today.
Novo Nordisk is up big today and Sanofi is flat (Novo had an upbeat call)
I think this news below is bullish for Sanofi.
"With Novo poised to launch its second-generation basal insulin Tresiba in the United States in 2016 or 2017 and Lilly readying its biosimilar in 2016, wringing out price increases after next year will be all but impossible," Evaluate Pharma, an industry newsletter, said.
Novo Nordisk's big hope for the future is Tresiba, which the U.S. Food & Drug Administration (FDA) refused to approve in February last year, demanding more tests. The unexpected decision was a big blow to the company and its shares plummeted.
On Thursday, it presented a more cautious assessment of when it would submit more data to the FDA and subsequently launch the drug.
-----
Lantus is going to struggle against generics in the first part of the year and Sanofi will face margin contraction in face of generics coming on to the market. But, their next generation product will do well with Tresiba delays. I think analysts will come out after the new CEO is announced saying the sell off was overdone.
|
|
|
|
Post by jpg on Oct 30, 2014 14:11:39 GMT -5
I don't remember who suggested a pair trade of Sanofi (long) and Novo Nordisk (short) but now might be a good time to begin it...
JPG
|
|
